Indication

In combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Medicine details

Medicine name:
daratumumab (Darzalex)
SMC ID:
SMC2302
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
11 January 2021
SMC meeting date:
01 December 2020
Patient group submission deadline:
05 October 2020